Systemic lupus erythematosus (SLE) is an autoimmune disorder that involves multiple organs and has alternating periods of flare-ups and quiescence. The availability of modern biologic treatments for SLE has resulted in high expectations for reduced morbidity and mortality; however, there are also concerns about the accelerating costs of the new drugs. Information on the costs attributed to illness in different subgroups of SLE patients is needed to enable cost–benefit analyses.
This work was supported by a research grant from the research platform Combine based on an unrestricted grant from Glaxo SmithKline.
Lupus. 2015; 24(12): 1248-56